Patents Assigned to Merck
  • Patent number: 9938229
    Abstract: The present invention relates to polymerizable compounds, to processes and intermediates for the preparation thereof, to liquid-crystal (LC) media comprising them, and to the use of the polymerizable compounds and LC media for optical, electro-optical and electronic purposes, in particular in LC displays, especially in LC displays of the polymer sustained alignment type.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: April 10, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Eveline Baron, Julian Vogt, Qiong Tong, Constanze Brocke, Helga Haas, Alexander Hahn
  • Publication number: 20180092900
    Abstract: The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    Type: Application
    Filed: December 4, 2017
    Publication date: April 5, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Ian M. Bell, Mark E. Fraley, Steven N. Gallicchio, Anthony Ginetti, Helen J. Mitchell, Daniel V. Paone, Donnette D. Staas, Cheng Wang, C. Blair Zartman
  • Publication number: 20180092901
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.
    Type: Application
    Filed: March 3, 2016
    Publication date: April 5, 2018
    Applicants: MERCK SHARP & DOHME CORP., Eisai R&D Management Co., Ltd.
    Inventors: Andrew Evan DENKER, Yu KATO, Kimiyo TABATA, Yusaku HORI
  • Publication number: 20180092899
    Abstract: A method of alleviating or mitigating at least one symptom of migraine attack by administering to a patient suffering from a migraine attack a therapeutically effective amount of the compound of Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 29, 2017
    Publication date: April 5, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Chi-Chung Liu, David Michelson, Gene Marcantonio, Kyle Fliszer, Rebecca White, Mark Fraley, Leonardo Allain, Tiffani Voss, John Limanto
  • Publication number: 20180093964
    Abstract: Compounds of general formula (Ia), compounds of general formula (Ia?), compounds of general formula (Ib), compounds of general formula (Ib?), compounds of general formula (I), compounds of general formula (I?), and their pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5, R6, R8, R9, X1, X2, and X3 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds of the disclosure.
    Type: Application
    Filed: October 2, 2017
    Publication date: April 5, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Michael D. Altman, Brandon D. Cash, Wonsuk Chang, Jared N. Cumming, Andrew M. Haidle, Timothy J. Henderson, James P. Jewell, Matthew A. Larsen, Rui Liang, Jongwon Lim, Min Lu, Ryan D. Otte, Tony Siu, Benjamin Wesley Trotter, Sriram Tyagarajan
  • Patent number: 9931324
    Abstract: The present invention relates to indolizine compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: April 3, 2018
    Assignee: Merck Patent GmbH
    Inventors: Srinivasa R. Karra, Andreas Goutopoulos
  • Patent number: 9932350
    Abstract: The present invention relates to inhibitors of IRAK4 of Formula I and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: April 3, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Jason D. Brubaker, Matthew L. Childers, Anthony Donofrio, Thierry Fischmann, Craig R. Gibeau, Solomon D. Kattar, Charles A. Lesburg, Jongwon Lim, John K. F. Maclean, Umar F. Mansoor, Alan B. Northrup, John M. Sanders, Graham F. Smith
  • Patent number: 9932311
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: April 3, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Tesfaye Biftu, Purakkattle Biju, Steven L. Colletti, Mingxiang Cui, William K. Hagmann, Bin Hu, Hubert Josien, Nam Fung Kar, Anilkumar Nair, Ravi Nargund, Donald M. Sperbeck, Cheng Zhu
  • Patent number: 9931604
    Abstract: An apparatus for performing sonication on liquid samples comprises a rack for holding an array of sample vials, an ultrasonic probe with an arrangement of recesses corresponding to the array of sample vials and adapted to respectively receive and contact an outer surface of a bottom portion of a respective one of the sample vials, and a counter-holder with an arrangement of pushing members corresponding to the array of sample vials and adapted to respectively apply a force to a respective one of the sample vials so as to push the bottom portion of each vial into contact with the associated recess of the probe. The apparatus can be used in a method of preparing a sample for detection of cell components (e.g. cell analyte, proteins, nucleid acids etc.) and applying sonication within certain parameter ranges which can provide a universal lysis method that can be applied to a large variety of cells or organisms like all bacteria, viruses, spores, yeast and mold within the same apparatus and process.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: April 3, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Luc Felden, David Lehmann, Marisa Hohnadel, Sebastien Jouette
  • Patent number: 9932337
    Abstract: The present invention relates to methods for the production of enantiopure or enantioenriched Praziquantel precursors and to methods for the production of enantiopure or enantioenriched Praziquantel comprising the methods for the production of the Praziquantel precursors. The present invention further relates to compounds or intermediates useful in such methods.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: April 3, 2018
    Assignee: Merck Patent GmbH
    Inventors: David Maillard, Andreas Waechtler, Jeremy Maurin, Ewgenij Wakaresko, Christian Jasper
  • Patent number: 9931637
    Abstract: A support apparatus for a filter membrane comprises a base support and a disc-shaped porous support member. The member is removably received in a seat portion of the base support in fluid communication with a drain. A bottom side of the disc-shaped porous support member is supported in a support plane. The bottom side of the member is unsupported in an area and the unsupported area is adjacent to a space in the seat portion of the base support that is located and dimensioned such that application of a force, onto the top side of the member at a location substantially within the boundaries of the unsupported area at the bottom side will cause the member to pivot/tilt into the space and lift above the support plane at a diagonally opposite side from the location where the force is applied so that it can be easily grasped and removed.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: April 3, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Frederic Amstoutz, Vincent Schaal
  • Publication number: 20180086980
    Abstract: The invention relates to a liquid-crystalline medium, preferably having a nematic phase and dielectric anisotropy of 0.5 or more, which comprises one or more compounds of formula Y in which the parameters have the meanings given in the text, to the use thereof in an electro-optical display, particularly in an active-matrix display based on the IPS or FFS effect, to displays of this type which contain a liquid-crystalline medium of this type, and to the use of the compounds of formula Y for the improvement of the transmission and/or response times of a liquid-crystalline medium which comprises one or more additional mesogenic compounds.
    Type: Application
    Filed: September 25, 2017
    Publication date: March 29, 2018
    Applicant: MERCK PATENT GMBH
    Inventor: Atsutaka MANABE
  • Publication number: 20180086841
    Abstract: The present invention relates to anti-CD27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: September 25, 2017
    Publication date: March 29, 2018
    Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.
    Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise
  • Publication number: 20180085358
    Abstract: The present invention provides certain substituted chromane, isochromane, and dihydroisobenzofuran compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein ring A is a moiety selected from: and ring B, n, R1, R2, R2A, R3, and R3A are as defined herein. The compounds of the invention are useful as mGluR2 inhibitors, or mGluR2 negative allosteric modulators (NAMs), and may be useful in methods of treating a patient for diseases or disorders in which the mGluR2-NAM receptor is involved, such as Alzheimer's disease, cognitive impairment, mild cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 25, 2017
    Publication date: March 29, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Iyassu K. Sebhat, Ashok Arasappan, Scott B. Hoyt, Robert R. Wilkening, Duane DeMong
  • Patent number: 9929354
    Abstract: The present invention relates to compounds suitable for use in electronic devices, and to electronic devices, especially organic electroluminescent devices, comprising these compounds.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: March 27, 2018
    Assignee: Merck Patent GmbH
    Inventors: Philipp Stoessel, Elvira Montenegro, Arne Buesing, Teresa Mujica-Fernaud, Joachim Kaiser
  • Patent number: 9926341
    Abstract: The present invention relates to the isolation of recombinant and/or biotherapeutic proteins for capture or clarification from cell culture fluid using copolymers. The copolymers used according to the process of the present invention comprise hydrophobic and anionic residues.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: March 27, 2018
    Assignee: Merck Patent GmbH
    Inventors: Johann Bauer, Almut Rapp, Bernd Stanislawski, Florian Capito
  • Patent number: 9926317
    Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: March 27, 2018
    Assignee: Merck Sharp Dohme Corp.
    Inventors: Alexander Pasternak, Ian Davies, Fa-Xiang Ding, Jinglong Jiang, Shuzhi Dong, Xin Gu
  • Patent number: 9926285
    Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: March 27, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Brendan M. Crowley, Brian T. Campbell, Joseph L. Duffy, Andrew John Harvey, Ian M. Bell
  • Patent number: 9925196
    Abstract: Pharmaceutical compositions are provided in unit dosage forms comprising ceftolozane and tazobactam in separate unit dosage form containers, ceftolozane prepared in the absence of tazobactam, tazobactam prepared in the absence of ceftolozane, and/or compositions where ceftolozane and tazobactam are first combined within a unit dosage form container.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: March 27, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Joseph Terracciano, Nicole Miller Damour, Chun Jiang, Giovanni Fogliato, Giuseppe Alessandro Donadelli, Dario Resemini
  • Patent number: 9926330
    Abstract: The present invention relates to inhibitors of IRAK4 of Formula I and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: March 27, 2018
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Michael D. Altman, Jason D. Brubaker, Matthew L. Childers, Anthony Donofrio, Thierry Fischmann, Craig R. Gibeau, Solomon D. Kattar, Charles A. Lesburg, Jongwon Lim, John K. F. MacLean, Umar F. Mansoor, Alan B. Northrup, John M. Sanders, Graham F. Smith